---
$id: https://graph.org.ai/products/commodity/51131739
$type: Product
source: UNSPSC
code: "51131739"
title: "Taprostene"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Taprostene

**UNSPSC Code**: 51131739
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C24H30O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7MS1HEY2IZ, chemically known as benzoic acid, 3-((4-(3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, (3ar-(2z,3a-alpha,4-alpha(1e,3s*),5-beta,6a-alpha))- but generally known as taprostene, which bears US NIH Compound Identifier 5311243. European Medicines Agency schedules Taprostene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10831MIG. The term TAPROSTENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, No. 3, 1988, List 28). TAPROSTENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule taprostene under HS 29375000 and SITC 54156. As of Q4 2014, TAPROSTENE remains the US FDA Preferred Term for this commodity. Taprostene bears US NLM identifiers UMLS ID C0075812 and NCI Concept Code C76403. SMILES: O1C2C(C(C(O)C2)/C=C/C(O)C2CCCCC2)CC\1=C\C1CC(CCC1)C(=O)O.

